- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
This study is looking at a new medicine called CT-P13 for adults with moderate to severe rheumatoid arthritis. Researchers want to see if it helps reduce symptoms and is safe to use. Some people will get the new medicine, and others will get a dummy medicine to compare.
For: Rheumatoid arthritisPoland - AuthorisedPhase I and Phase II (Integrated)- Other
The headache- and migraine-inducing effects of pitolisant in women with migraine without aura
This study looks at how a medicine called pitolisant affects headaches and migraines in women who already get migraines. Researchers want to see if it causes more migraine-like headaches compared to a dummy pill or other common migraine treatments.
For: Migraine without auraDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter, double-blind, randomized, placebo-controlled, dose-response trial with the full-spectrum Cannabis Extract VER-01 in patients with chronic non-specific low back pain
For: For the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.Germany · Czechia · Spain - Ongoing, recruitingTherapeutic use (Phase IV)
Perioperative oral analgesia versus intravenous analgesia for knee arthroscopy, a randomized, double-blinded, non-inferiority trial. OVIKA-trial - S68618
For: Postoperative pain relief after knee arthroscopyBelgium - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension
For: Glycogen storage disease type 1a (GSD1a)Spain · Poland · Netherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria
For: Participants with PhenylketonuriaFrance · Spain · Italy